Company Profiles

driven by the PitchBook Platform

DNAtrix

Description

Developer of virus-driven immunotherapies for cancer. The company's lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, an incurable brain cancer and the company's pipeline includes viruses armed with potent immunomodulatory molecules that augment a patient's immune system to trigger an aggressive anti-tumor T-cell response.

2005

Founded

PRIVATE

Status

11-50

Employees

Series B

Latest Deal Type

$19.8M

Latest Deal Amount

$21.8M

Total Amount Raised

Description

Developer of virus-driven immunotherapies for cancer. The company's lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, an incurable brain cancer and the company's pipeline includes viruses armed with potent immunomodulatory molecules that augment a patient's immune system to trigger an aggressive anti-tumor T-cell response.

Website:

www.dnatrix.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

2450 Holcombe Boulevard Houston, TX 77021United States +1 (832) 930-2401
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore DNAtrix's full profile, request a free trial.

DNAtrix Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

DNAtrix Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

DNAtrix Investors (11)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
CPRITOtherMinority000 0000000 0000
JLabsAccelerator/IncubatorMinority000 0000000 0000
Mercury FundVenture CapitalMinority000 0000000 0000
Morningside GroupVenture CapitalMinority000 0000000 0000
Targeted TechnologyVenture CapitalMinority000 0000000 0000
CPRIT Other
JLabs Accelerator/Incubator
Mercury Fund Venture Capital
Morningside Group Venture Capital
Targeted Technology Venture Capital

DNAtrix Executive Team (12)

NameTitleBoard
Seat
Contact
Info
Frank Tufaro Ph.DChief Executive Officer & Board Member
Brian MooneyChief Financial Officer
Imran Alibhai Ph.DManaging Director & Senior Vice President, Business Development
Imre Kovesdi Ph.DChief Scientific Officer & Senior Vice President, Research
Erin Mitchell Ph.DVice President, Manufacturing & Director, Manufacturing
Frank Tufaro Ph.D Chief Executive Officer & Board Member
Brian Mooney Chief Financial Officer
Imran Alibhai Ph.D Managing Director & Senior Vice President, Business Development
Imre Kovesdi Ph.D Chief Scientific Officer & Senior Vice President, Research
Erin Mitchell Ph.D Vice President, Manufacturing & Director, Manufacturing

DNAtrix Board Members (5)

NameRepresentingRoleSinceContact
Info
Daniel Watkins Ph.DMercury FundPartner000 0000
Drew Pardoll Ph.DDNAtrixBoard Member000 0000
Francis McCormickSelfBoard Member000 0000
Frank Tufaro Ph.DDNAtrixChief Executive Officer & Board Member000 0000
Reenie McCarthy JDMorningside GroupDirector000 0000
Daniel Watkins Ph.D Partner Mercury Fund
Drew Pardoll Ph.D Board Member DNAtrix
Francis McCormick Board Member Self
Frank Tufaro Ph.D Chief Executive Officer & Board Member DNAtrix
Reenie McCarthy JD Director Morningside Group
Request full access to PitchBook